Impact of left venticular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes

Journal of Heart and Lung Transplantation

Volumn 24, Issue 12, 2005, Pages 2054-2059

  Joyce, David L ^a   Southard, Robert E ^a   Torre Amione, Guillermo ^a   Noon, George P ^a   Land, Geoffrey A ^b   Loebe, Matthias ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; HEART ASSIST DEVICE; HEART GRAFT; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MORTALITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; REGISTER; SENSITIZATION; TREATMENT OUTCOME; ANTIBODY PRODUCTION; COMPARATIVE STUDY; GRAFT REJECTION; IMMUNOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS; SURVIVAL;

ANTIBODY FORMATION; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 29144511605     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2005.06.028     Document Type: Article

References (20)

1. J. Lavee, R.L. Kormos, R.J. Duquesnoy Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation J Heart Lung Transplant 10 1991 921 929
2. J.A. Kobashigawa, A. Sabad, D. Drinkwater Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 94 suppl 1996 II-294 II-297
3. P.J. Michaels, M.L. Espejo, J. Kobashigawa Humoral rejection in cardiac transplantation risk factors, hemodynamic consequences and relationship to transplant coronary artery disease J Heart Lung Transplant 22 2003 58 69
4. A.S. Betkowski, R. Graff, J.J. Chen, P.J. Hauptman Panel-reactive antibody screening practices prior to heart transplantation J Heart Lung Transplant 21 2002 644 650
5. J.C. Stringham, D.A. Bull, T.C. Fuller Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization J Heart Lung Transplant 18 1999 160 165
6. G.S. Kumpati, D.J. Cook, E.H. Blackstone HLA sensitization in ventricular assist device recipients does type of device make a difference? J Thorac Cardiovasc Surg 127 2004 1800 1807
7. D.O. Taylor, L.B. Edwards, M.M. Boucek, E.P. Trulock, B.M. Keck, M.I. Hertz The registry of the International Society for Heart and Lung Transplantation twenty-first official adult heart transplant report - 2004 J Heart Lung Transplant 23 2004 796 803
8. E.A. Rose, A.C. Gelijns, A.J. Moskowitz Long-term mechanical left ventricular assistance for end-stage heart failure N Engl J Med 345 2001 1435 1443
9. K.L. Grady, P.M. Meyer, D. Dressler Change in quality of life from after left ventricular assist device implantation to after heart transplantation J Heart Lung Transplant 22 2003 1254 1267
10. K.L. Grady, P.M. Meyer, A. Mattea Change in quality of life from before to after discharge following left ventricular assist device implantation J Heart Lung Transplant 22 2003 322 333
11. R. John, K. Lietz, E. Burke Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients Circulation 100 suppl 1999 II-229 II-235
12. S. Itescu, E. Burke, K. Lietz Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients Circulation 105 2002 1214 1219
13. P.H. Tsau, F.A. Arabia, B. Toporoff, V. Paramesh, G.K. Sethi, J.G. Copeland Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device risk factors and treatment ASAIO J 44 1998 M634 M637
14. M.G. Massad, P.M. McCarthy, N.G. Smedira Does successful bridging with the implantable left ventricular assist device affect cardiac transplantation outcome? J Thorac Cardiovasc Surg 112 1996 1275 1281
15. S. Itescu, T.C. Tung, E.M. Burke Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation Circulation 98 1998 786 793
16. F.D. Pagani, D.B. Dyke, S. Wright, R. Cody, K.D. Aaronson Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation effects on subsequent allograft rejection and survival J Heart Lung Transplant 20 2001 646 653
17. N. Moazami, S. Itescu, M.R. Williams, M. Argenziano, A. Weinberg, M.C. Oz Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support J Heart Lung Transplant 17 1998 876 880
18. M.G. Massad, D.J. Cook, S.K. Schmitt Factors influencing HLA sensitization in implantable LVAD recipients Ann Thorac Surg 64 1997 1120 1125
19. R. John, K. Lietz, M. Schuster Immunologic sensitization in recipients of left ventricular assist devices J Thorac Cardiovasc Surg 125 2003 578 591
20. A. Geirsson, A.L. Bothwell, G.L. Hammond Inhibition of alloresponse by a human trophoblast non-coding RNA suppressing class II transactivator promoter III and major histocompatibility class II expression in murine B-lymphocytes J Heart Lung Transplant 23 2004 1077 1081